Akademska digitalna zbirka SLovenije - logo
MF, Central Medical Library, Lj. (CMK)
Poletni urnik (1.7. do 31.8.2024): ponedeljek do četrtek: 9.00-15.00, petek: 9.00-13.00.
26.7., 15.8. in 16.8. 2024 bo knjižnica ZAPRTA.
  • Immediate platelet inhibition strategy for comatose out-of-hospital cardiac arrest survivors undergoing percutaneous coronary intervention and mild therapeutic hypothermia [Elektronski vir]
    Kordiš, Peter, dr. med. ...
    Background: Comatose survivors of out-of-hospital cardiac arrest (OHCA) undergoing percutaneous coronary intervention (PCI) and target temperature management (TTM) are at increased risk of stent ... thrombosis (ST), partly due to delayed platelet inhibition even with more potent P2Y12 agents. We hypothesized that periprocedural cangrelor would induce immediate platelet inhibition, bridging the "P2Y12 inhibition gap". Methods: In our pilot study, we randomized 30 comatose OHCA patients undergoing PCI and TTM (32-34 °C) into cangrelor and control groups. Both groups received unfractioned heparin, acetylsalicylic acid, and ticagrelor via enteral tube. The cangrelor group also received an intravenous bolus of cangrelor followed by a 4 h infusion. Platelet inhibition was measured using VerifyNow® and Multiplate® ADP at baseline and 1, 3, 5, and 8 h post PCI. Results: Patient characteristics did not differ between groups. VerifyNow® showed significantly decreased platelet reactivity with cangrelor at 1 h (30 vs. 221 PRU; p < 0.001) and 3 h (24 vs. 180 PRU; p < 0.001), with differences at 5 and 8 h. Similarly, the proportion of patients with high on-treatment platelet reactivity (HPR) in the cangrelor group was significantly lower at 1 h (0% vs. 67%; p < 0.001) and 3 h (0% vs. 47%; p = 0.007). Multiplate® ADP was also decreased at 1 h (14 vs. 48 U; p < 0.001) and 3 h (11 vs. 42 U; p = 0.001), with no difference at 5 and 8 h. The occurrence of bleeding events was similar in both groups. Conclusions: Cangrelor safely induced immediate and profound platelet inhibition. We observed no significant drug-drug interaction with ticagrelor.
    Source: Journal of clinical medicine [Elektronski vir]. - ISSN 2077-0383 (Vol. 13, iss. 7, [article no.] 2121, 2024, str. 1-13)
    Type of material - e-article ; adult, serious
    Publish date - 2024
    Language - english
    COBISS.SI-ID - 194020099

    Link(s):

    https://www.mdpi.com/2077-0383/13/7/2121
    DOI

Shelf entry